GuidelineAnnals of the rheumatic diseases2017
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Guideline in Annals of the rheumatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 84 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment With add-on IVIg in Myositis Early In the diSease Course May be sUperior to Steroids Alone for Reaching CLinical improvemEnt
Real-world Experience With Deucravacitinib for the Treatment of Idiopathic Inflammatory Myopathies -- a Prospective Observational Study
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.The Cochrane database of systematic reviews · 2025Pooled it
- Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.The Cochrane database of systematic reviews · 2025Pooled it
- Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review.Rheumatology international · 2025Pooled it
- Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease.Rheumatology (Oxford, England) · 2025Trial
- High-intensity resistance training improves quality of life, muscle endurance and strength in patients with myositis: a randomised controlled trial.Rheumatology international · 2024Trial
- Belimumab treatment of adult idiopathic inflammatory myopathy.Rheumatology (Oxford, England) · 2024Trial
- Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis.Clinical rheumatology · 2023Trial
- The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.Pediatric rheumatology online journal · 2019Trial
- Fibrosing myopathy in systemic sclerosis: Treatment response and clinical outcomes in a distinct subset.Seminars in arthritis and rheumatism · 2026Article
- Flares and definition of worsening in inflammatory myopathies: a narrative review of the literature.Rheumatology (Oxford, England) · 2026Review
- Fibromyalgia in patients with idiopathic inflammatory myopathies: prevalence, associated factors, and relationship with patient outcomes and health care utilization.Clinical rheumatology · 2026Article
- Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients.Journal of neurology · 2026Article
- High frequency of interstitial lung disease in Indian patients with adult- onset idiopathic inflammatory myopathy: Insights from a prospective observational cohort.Clinical rheumatology · 2026Observational
- Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies.Rheumatology (Oxford, England) · 2026Article
- The Role of Ultrasound Pleural Irregularities in the Identification of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies.Journal of personalized medicine · 2026Article
- CAR-T therapy for autoimmune rheumatic diseases: navigating clinical frontiers between breakthroughs and uncertainties.Clinical and experimental medicine · 2026Review
- Chimeric antigen receptor T-cell therapy for rheumatic diseases: from B-cell depletion to immune reset and beyond.Frontiers in immunology · 2026Review
- Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study.Clinical, cosmetic and investigational dermatology · 2026Article
- The Distinct Monocyte Subsets and Intercellular Communication in Primary Sjögren's Syndrome Revealed by Single-Cell RNA Sequencing.Journal of clinical immunology · 2025Article
- Sit to stand and timed up and go in idiopathic inflammatory myopathies.Scientific reports · 2025Observational
24 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors.
Funding
Abstract
To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. Consensus was reached for a conjoint analysis-based continuous model using absolute per cent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (p<0.001). The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute per cent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.